Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells.
Amsacrine is an acridine derivative drug applied in haematological malignancies. It targets topoisomerase II enhancing the formation of a cleavable DNA-enzyme complex and leading to DNA fragmentation in dividing cancer cells. Little is known about other modes of the interaction of amsacrine with DNA, by which it could affect also normal cells. Using the alkaline comet assay, we showed that amsacrine at concentrations from the range 0.01 to 10 microM induced DNA damage in normal human lymphocytes, human promyelocytic leukemia HL-60 cells lacking the p53 gene and murine pro-B lymphoid cells BaF3 expressing BCR/ABL oncogene measured as the increase in percentage tail DNA. The effect was dose-dependent. Treated cells were able to recover within a 120-min incubation. Amifostine at 14 mM decreased the level of DNA damage in normal lymphocytes, had no effect on the HL-60 cells and potentiated the DNA-damaging effect of the drug in BCR/ABL-transformed cells. Vitamin C at 10 and 50 microM diminished the extent of DNA damage in normal lymphocytes, but had no effect in cancer cells. Pre-treatment of the cells with the nitrone spin trap, N-tert-butyl-alpha-phenylnitrone or ebselen, which mimics glutathione peroxidase, reduced the extent of DNA damage evoked by amsacrine in all types of cells. The cells exposed to amsacrine and treated with endonuclease III and 3-methyladenine-DNA glycosylase II, the enzymes recognizing oxidized and alkylated bases, respectively, displayed greater extent of DNA damage than those not treated with these enzymes. The results obtained suggest that free radicals may be involved in the formation of DNA lesions induced by amsacrine. The drug can also methylate DNA bases. Our results indicate that the induction of secondary malignancies should be taken into account as diverse side effects of amsacrine. Amifostine may potentate DNA-damage effect of amsacrine in cancer cells and decrease this effect in normal cells and Vitamin C can be considered as a protective agent against DNA damage in normal cells.
Blasiak
Janusz
J
Department of Molecular Genetics, University of Lodz, Lodz, Poland. junuszb@biol.uni.lodz.pl
Gloc
Ewa
E
Drzewoski
Jozef
J
Wozniak
Katarzyna
K
Zadrozny
Marek
M
Skórski
Tomasz
T
Pertynski
Tomasz
T
D000328:Adult; D004999:Amifostine / Q000494:pharmacology; D000677:Amsacrine / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology; D001393:Azoles / Q000494:pharmacology; D002461:Cell Line, Transformed; D020552:Comet Assay; D003497:Cyclic N-Oxides; D004249:DNA Damage; D004260:DNA Repair; D004305:Dose-Response Relationship, Drug; D016166:Free Radical Scavengers / Q000494:pharmacology*; D018922:HL-60 Cells; D006801:Humans; D066298:In Vitro Techniques; D054833:Isoindoles; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D009153:Mutagens / Q000008:administration & dosage / Q000633:toxicity*; D009589:Nitrogen Oxides / Q000494:pharmacology; D016566:Organoselenium Compounds / Q000494:pharmacology
D001393:Azoles; D003497:Cyclic N-Oxides; D016166:Free Radical Scavengers; D054833:Isoindoles; D009153:Mutagens; D009589:Nitrogen Oxides; D016566:Organoselenium Compounds; D000677:Amsacrine; C029217:phenyl-N-tert-butylnitrone; C042986:ebselen; D004999:Amifostine; D001205:Ascorbic Acid